Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT00135811 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Focal Segmental Glomerulosclerosis Clinical Trial (FSGS-CT)

StatusCompleted
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Results first posted: Sep 18, 2026 Primary endpoint revised · Enrollment target: estimated 207 to confirmed 192 · Primary and study completion dates: Oct 2009 to Nov 2009 · 3 morev15 Show 6 more changesShow less
    • Primary endpoint revised
    • Enrollment target: estimated 207 to confirmed 192
    • Primary and study completion dates: Oct 2009 to Nov 2009
    • Interventions: Cyclosporin (Drug), MMF and Dexamethasone (Drug) to Cyclosporin (Drug), Mycophenolate mofetil and Dexamethasone (Drug)
    • Secondary endpoint revised
    • Publications: details revised at 1 of 5 entries

    See this version in full on ClinicalTrials.gov ↗

  2. Re-verified, no change to tracked fieldsv14
  3. Trial status: Active, Not Recruiting to Completedv13
  4. 2 versions Re-verified since Feb 4, 2011, no change to tracked fieldsv11-v12
  5. Primary and study completion dates: Oct 2008 to Oct 2009 Trial status: Recruiting to Active, Not Recruiting · Site details revisedv10 Show 2 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
Show 8 earlier versionsHide 8 earlier versions
  1. Primary completion date: Oct 2008v9
  2. Interventions: Cyclosporin (CSA) (Drug), Mycophenolate Mofetil (MMF) (Drug) to Cyclosporin (Drug), MMF and Dexamethasone (Drug) Secondary endpoints: details revised at 1 of 1 entry · Study arms: 0 to 2 · Collaborators expanded, about 3 wordsv8 Show 3 more changesShow less
    • Secondary endpoints: details revised at 1 of 1 entry
    • Study arms: 0 to 2
    • Collaborators expanded, about 3 words

    See this version in full on ClinicalTrials.gov ↗

  3. Enrollment target: 500 to 207 Study site revisedv7 Show 1 more changeShow less
    • Study site revised

    See this version in full on ClinicalTrials.gov ↗

  4. 4 versions Re-verified since Feb 2, 2006, no change to tracked fieldsv3-v6
  5. Interventions: Cyclosporin (CSA) and Mycophenolate Mofetil (MMF) (Drug) to Cyclosporin (CSA) (Drug), Mycophenolate Mofetil (MMF) (Drug) Secondary endpoint revised · Eligibility criteria shortened, about 3 words · Study description shortened, about 5 words · 1 morev2 Show 4 more changesShow less
    • Secondary endpoint revised
    • Eligibility criteria shortened, about 3 words
    • Study description shortened, about 5 words
    • Study title expanded, about 2 words

    See this version in full on ClinicalTrials.gov ↗

  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The FSGS Clinical Trial is a multi-center, prospective, controlled, open label randomized trial designed to determine if treatment with mycophenolate mofetil (MMF) in conjunction with pulse steroids is superior to treatment with Cyclosporine-A (CSA) in inducing remission from proteinuria over 12 months.
Trial Details
NCT Number NCT00135811
Lead Sponsor National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborators: The Cleveland Clinic
Conditions Glomerulosclerosis, Focal
Enrollment 192 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov